Astegolimab is a selective ST2 IgG2 monoclonal antibody developed to treat asthma and chronic obstructive pulmonary disease. It is expected to be efficacious for patients with low eosinophil count.[1] It is developed by Genentech/Roche.[2][3][4][5][6][7][8]
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| Other names | AMG282; AMG-282 |
| Routes of administration | SC, IV |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
References
edit- ^ "Astegolimab: Vorteil bei niedriger Eosinophilenzahl?". Home (in German). Retrieved 2024-08-05.
- ^ Sperinde, Gizette; Dolton, Michael; Zhang, Wenhui; Mathews, Joel; Putnam, Wendy; Fischer, Saloumeh K (November 2023). "Factors contributing to the nonlinear pharmacokinetics of astegolimab: a close examination of potential causes". Bioanalysis. 15 (21): 1305–1314. doi:10.4155/bio-2023-0115. PMID 37791725. S2CID 263621694.
- ^ Waters, Michael; McKinnell, James A.; Kalil, Andre C.; Martin, Greg S.; Buchman, Timothy G.; Theess, Wiebke; Yang, Xiaoying; Lekkerkerker, Annemarie N.; Staton, Tracy; Rosenberger, Carrie M.; Pappu, Rajita; Wang, Yehong; Zhang, Wenhui; Brooks, Logan; Cheung, Dorothy; Galanter, Joshua; Chen, Hubert; Mohan, Divya; Peck, Melicent C. (January 2023). "Astegolimab or Efmarodocokin Alfa in Patients With Severe COVID-19 Pneumonia: A Randomized, Phase 2 Trial*". Critical Care Medicine. 51 (1): 103–116. doi:10.1097/CCM.0000000000005716. ISSN 0090-3493. PMC 9749945. PMID 36519984.
- ^ Kotani, Naoki; Dolton, Michael; Svensson, Robin J.; Ribbing, Jakob; Friberg, Lena E.; Vadhavkar, Shweta; Cheung, Dorothy; Staton, Tracy; Sperinde, Gizette; Jin, Jin; Putnam, Wendy S.; Quartino, Angelica (July 2022). "Population Pharmacokinetics and Exposure‐Response Relationships of Astegolimab in Patients With Severe Asthma". The Journal of Clinical Pharmacology. 62 (7): 905–917. doi:10.1002/jcph.2021. ISSN 0091-2700. PMC 9303772. PMID 34964491.
- ^ Maurer, Marcus; Cheung, Dorothy S.; Theess, Wiebke; Yang, Xiaoying; Dolton, Michael; Guttman, Anna; Choy, David F.; Dash, Ajit; Grimbaldeston, Michele A.; Soong, Weily (December 2022). "Phase 2 randomized clinical trial of astegolimab in patients with moderate to severe atopic dermatitis". Journal of Allergy and Clinical Immunology. 150 (6): 1517–1524. doi:10.1016/j.jaci.2022.08.015. PMID 36041655. S2CID 251890548.
- ^ Yousuf, Ahmed J; Mohammed, Seid; Carr, Liesl; Yavari Ramsheh, Mohammadali; Micieli, Claudia; Mistry, Vijay; Haldar, Kairobi; Wright, Adam; Novotny, Petr; Parker, Sarah; Glover, Sarah; Finch, Joanne; Quann, Niamh; Brookes, Cassandra L; Hobson, Rachel; Ibrahim, Wadah; Russell, Richard J; John, Catherine; Grimbaldeston, Michele A; Choy, David F; Cheung, Dorothy; Steiner, Michael; Greening, Neil J; Brightling, Christopher E (May 2022). "Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial". The Lancet Respiratory Medicine. 10 (5): 469–477. doi:10.1016/S2213-2600(21)00556-7. PMID 35339234. S2CID 247718726.
- ^ Kelsen, Steven G.; Agache, Ioana O.; Soong, Weily; Israel, Elliot; Chupp, Geoffrey L.; Cheung, Dorothy S.; Theess, Wiebke; Yang, Xiaoying; Staton, Tracy L.; Choy, David F.; Fong, Alice; Dash, Ajit; Dolton, Michael; Pappu, Rajita; Brightling, Christopher E. (September 2021). "Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial". Journal of Allergy and Clinical Immunology. 148 (3): 790–798. doi:10.1016/j.jaci.2021.03.044. PMID 33872652. S2CID 233308659.
- ^ Comellas, Alejandro P; Fortis, Spyridon (1 November 2023). "Blood eosinophil-guided therapy for COPD exacerbations". The Lancet Respiratory Medicine. 12 (1): 9–10.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |